Integrating New Therapies Into the Management of Relapsed/Refractory Myeloma: Experts Address FAQs
CCO Oncology Podcast
English - August 24, 2021 20:30 - 26 minutes - 24.6 MBCourses Education Health & Fitness Medicine essential thrombocythemia myelofibrosis oncology cme skin cancer acute myeloid leukemia kidney cancer melanoma gastrointestinal cancer prostate can Homepage Download Google Podcasts Overcast Castro Pocket Casts RSS feed
In this episode, Paul G. Richardson, MD; Nina Shah, MD; and Peter M. Voorhees, MD, answer questions from a live webinar providing their thoughts on how to select the optimal therapy for patients with relapse/refractory multiple myeloma. Topics include:
Treatment after first relapsedOptimal use of CAR T-cell therapyWhen to use selinexor and belantamab mafodotinCOVID-19 vaccinations for patients with myelomaPresenters:
Paul G. Richardson, MD
R. J. Corman Professor of Medicine
Harvard Medical School
Clinical Program Leader
Director of Clinical Research
Jerome Lipper Multiple Myeloma Center
Dana-Farber Cancer Institute
Boston, Massachusetts
Nina Shah, MD
Professor of Clinical Medicine
Division of Hematology-Oncology
Department of Medicine
University of California San Francisco
San Francisco, California
Peter M. Voorhees, MD
Director, Medical Operations and Outreach Services
Department of Hematology/Oncology
Levine Cancer Institute, Atrium Health
Charlotte, North Carolina
Content based on an online CME program supported by educational grants from Bristol-Myers Squibb, GlaxoSmithKline, Karyopharm, Oncopeptides, and Sanofi Genzyme.
Link to full program:
https://bit.ly/2UIhXcL